Is Revvity (RVTY) overvalued or fairly valued?

MarketChacha shows Revvity's valuation in context — a forward P/E of about 18.9, a price-to-book of about 1.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Revvity (RVTY)?

Revvity last traded at $110.35 (-0.2% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Revvity

RVTY · NYSE · Healthcare · United States

$110.35-0.2%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:34 PM

Snapshot

TickerRVTY

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees11,000

HeadquartersWaltham, United States

Market cap$12.3B

P/B1.7

Volume650.89K

Websitewww.revvity.com

Filings tracked0

About Revvity

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.4%
Institutions99.6%
Public & other0.0%

724 institutional holders

As reported by Yahoo Finance.

Top holders

T. Rowe Price Investment Management, Inc.19.90%
Price (T.Rowe) Associates Inc9.04%
Edgepoint Investment Group Inc.7.89%
Janus Henderson Group PLC7.48%
Vanguard Capital Management LLC6.57%
Blackrock Inc.6.50%
Vanguard Portfolio Management LLC4.31%
State Street Corporation3.86%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $691.6M · EPS 1.31

Est. earnings growth +11.4%

Next fiscal year

Rev $3.0B · EPS 5.84

Est. earnings growth +11.0%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$81.2252-wk range$118.30

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about RVTY

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.